Recent findings have unveiled some integrins are associated with Mendelian conditions. In a recent study, researchers directed efforts toward studying integrin-beta 8 (ITGB8) and its association with pathology, especially with neurological pathology, as none of them have been linked to neuropathology to date.

Circuit dysfunction is clearly recognized as a driver of neuropsychiatric disease, and some neurodegenerative diseases such as Parkinson’s disease. And at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022 Congress, researchers made an argument that the same is true in multiple sclerosis (MS). Such a lens could explain the radiological-clinical paradox between the amount of structural damage and clinical severity.

Cellevolve Bio Inc. announced that the FDA has cleared its IND application for CE-VST01-JC, an allogeneic, off-the-shelf, JC-specific T-cell therapy (JC-VST) targeting JC polyoma virus (JCV), being studied for the treatment of progressive multifocal leukoencephalopathy (PML).

Cour Pharmaceuticals Inc. announced that the FDA has cleared an IND application to initiate a phase Ib/IIa proof-of-concept study of its...

Reduced expression of nuclear factor erythroid 2-related factor 2 (Nrf2) is observed in humans and animal models of Alzheimer’s disease (AD), with its activation being a promising therapeutic approach.

Gb Sciences Inc. has received promising preclinical results in an interim report from a study using its plant-based compounds in preclinical zebrafish models of stress at the National Research Council of Canada (NRC).

Enveric Biosciences Inc. has nominated EB-373 as the lead development candidate to emerge from its EVM201 program. EB-373 is under development for the treatment of anxiety disorders.